Assessment of primary care provider and pharmacist knowledge, comfort, and barriers to appropriate inhaled corticosteroid use in chronic obstructive pulmonary disease

Author:

Foster Brooke12ORCID,Obidare‐Kolade Daniel2,Nagy Michael23ORCID

Affiliation:

1. Froedtert Health Milwaukee Wisconsin USA

2. Medical College of Wisconsin School of Pharmacy Milwaukee Wisconsin USA

3. Clement J. Zablocki Veterans Affairs Medical Center Milwaukee Wisconsin USA

Abstract

AbstractPharmacotherapeutic management of chronic obstructive pulmonary disease (COPD) primarily involves the use of inhaled bronchodilators and inhaled corticosteroids (ICS). Mounting evidence in recent years suggests ICSs should be reserved for a limited COPD population. This study set out to understand primary care pharmacist and primary care provider comfort, barriers, and knowledge regarding appropriate ICS use in COPD. A cross‐sectional, survey‐based study was conducted. The survey was shared with primary care providers and primary care pharmacists at two healthcare organizations in Southeastern Wisconsin. Descriptive statistics were employed to summarize the survey results. The primary outcome was level of comfort, as reported using a 7‐point Likert scale of participants with five statements related to managing ICSs in patients with COPD. Secondary outcomes were level of agreeance, as reported using a 7‐point Likert scale of participants to the existence of seven different barriers to successfully executing ICS de‐escalation. Escalation in patients with COPD who qualify and percentage of participants who correctly answered a select‐all‐that‐apply knowledge‐check question regarding appropriate patient factors for ICS de‐escalation. Participants were most uncomfortable with creating a tapering schedule for ICS de‐escalation. Most participants agreed that many barriers exist to executing appropriate ICS de‐escalations. Twenty percent of all participants answered the knowledge‐check question completely correctly. The study's findings suggest the surveyed primary care providers and pharmacists are uncomfortable with several aspects of COPD management. There are many barriers that prevent clinicians from de‐escalating ICSs in appropriate patients. Clinicians may have knowledge gaps regarding what factors make patients appropriate for ICS de‐escalation.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacy

Reference19 articles.

1. World Health Organization (WHO).Chronic Obstructive Pulmonary Disease (COPD). Available from:https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

2. Global Initiative for Chronic Obstructive Lung Disease (GOLD).Global Strategy for the Diagnosis Management and Prevention of Chronic Obstructive Pulmonary Disease: 2023 Report. 2022. Available from:https://goldcopd.org/2023-gold-report-2/

3. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease

4. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

5. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3